UNSPSC 51132236: Aspirin/dihydroxyaluminum aminoacetate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132236 Aspirin/dihydroxyaluminum aminoacetate is a Commodity code that, based on recent state and local solicitations, encompasses pharmaceutical products and over-the-counter medications supplied to public health agencies, emergency services, and multistate cooperative purchasing alliances. State and local governments buying under this code procure both brand-name and generic pharmaceuticals, naloxone and drug-deactivation systems for community health initiatives, and OTC products for distribution across government facilities. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These buyers typically issue RFPs and RFQs to establish supply contracts with manufacturers and authorized wholesalers, often structured as multi-award vehicles serving multiple jurisdictions over two-year terms with renewal options.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, based on recent solicitations. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, with bids due July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information for a direct-to-manufacturer prescription program that would bypass traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must comply with cGMP standards, Drug Supply Chain Security Act requirements, FDA approvals, and often maintain significant commercial general liability and professional liability insurance coverage.